Department of Psychiatry, Burdwan Medical College and Hospital, Burdwan, West Bengal, India.
Indian J Psychiatry. 2014 Apr;56(2):197-9. doi: 10.4103/0019-5545.130510.
Amisulpride, the newly introduced antipsychotic in India, is claimed to be effective in both positive and negative symptom schizophrenia and related disorders, though it has little or no action on serotonergic receptors. Limbic selectivity and lower striatal dopaminergic receptor binding capacity causes very low incidence of EPS. But, in clinical practice, we are getting EPS with this drug even at lower doses. We have reported three cases of akathisia, acute dystonia, and drug-induced Parkinsonism with low doses of amisulpride. So, we should keep this side effect in mind when using amisulpride. In fact, more studies are required in our country to find out the incidence of EPS and other associated mechanism.
在印度新引入的抗精神病药氨磺必利据称对阳性和阴性症状的精神分裂症及相关障碍均有效,尽管它对 5-羟色胺能受体几乎没有作用或作用很小。边缘选择性和较低的纹状体多巴胺能受体结合能力导致 EPS 的发生率非常低。但是,在临床实践中,我们甚至在用较低剂量时也会出现 EPS。我们报告了三例氨磺必利引起的静坐不能、急性肌张力障碍和药物诱导的帕金森病。因此,在使用氨磺必利时我们应该注意到这种副作用。事实上,我们国家需要进行更多的研究来发现 EPS 的发生率和其他相关机制。